MedPath

Cardiomems

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:2

Trial Phases

1 Phases

Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Not Applicable
2 (100.0%)

Wireless, Intermittent Monitoring of Right Heart Pressures in HF

Not Applicable
Completed
Conditions
NYHA Class III Heart Failure
First Posted Date
2010-07-15
Last Posted Date
2015-01-19
Lead Sponsor
CardioMEMS
Target Recruit Count
17
Registration Number
NCT01162707
Locations
🇺🇸

Piedmont Hospital, Atlanta, Georgia, United States

🇺🇸

Ohio State University Hospital, Columbus, Ohio, United States

🇺🇸

Oklahoma Heart Hospital, Oklahoma City, Oklahoma, United States

and more 1 locations

EndoSure Sensor for Long-term Follow-up After Endovascular AAA Repair

Conditions
Aortic Aneurysm, Abdominal
First Posted Date
2009-01-29
Last Posted Date
2012-08-30
Lead Sponsor
CardioMEMS
Target Recruit Count
900
Registration Number
NCT00831870

CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients

Not Applicable
Completed
Conditions
Heart Failure, Congestive
First Posted Date
2007-09-19
Last Posted Date
2015-01-28
Lead Sponsor
CardioMEMS
Target Recruit Count
550
Registration Number
NCT00531661
Locations
🇺🇸

CardioMEMS Investigational Sites, Nationwide, Georgia, United States

News

Abbott's TEAM-HF Trial Aims to Optimize Heart Failure Treatment with AI-Powered Monitoring

Abbott has initiated the TEAM-HF clinical trial to enhance outcomes for patients experiencing worsening heart failure by leveraging AI and the CardioMEMS™ HF System.

CardioMEMS Implant Halves Hospital Admissions for Heart Failure Patients

A tiny CardioMEMS sensor implanted in the pulmonary artery significantly reduces hospital admissions for heart failure patients by 44%.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.